Welcome to LookChem.com Sign In|Join Free
  • or
(S,R)-((pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((2S,4R)-2-(((tert-butyldimethylsllyl)oxy)methyl)-4-hydroxypyrrolidin-1-yl) methanone) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

260418-25-5

Post Buying Request

260418-25-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

260418-25-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 260418-25-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,0,4,1 and 8 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 260418-25:
(8*2)+(7*6)+(6*0)+(5*4)+(4*1)+(3*8)+(2*2)+(1*5)=115
115 % 10 = 5
So 260418-25-5 is a valid CAS Registry Number.

260418-25-5Relevant academic research and scientific papers

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

-

Page/Page column 202-203, (2016/10/31)

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody that binds CD19 and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzod

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

-

Page/Page column 201-202, (2016/10/31)

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds CD25 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiaze

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

-

Page/Page column 201-202, (2016/11/02)

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, all

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

-

Page/Page column 201-202, (2016/11/02)

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds HER2 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiaze

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

-

Page/Page column 216-217, (2016/10/31)

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, all

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

-

Page/Page column 206; 207, (2016/10/31)

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and pyrrolobenzo

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

-

Page/Page column 209; 210, (2016/10/31)

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds MUC1 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiaze

PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

-

Page/Page column 58, (2015/04/28)

Conjugates of specific PBD dimers with an antibody that that binds to HER2, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.

PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

-

Page/Page column 58, (2015/04/28)

Conjugates of specific PBD dimers with an antibody that that binds to CD19, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 2, 3, 4, 5 or 6, optionally further comprising a VL domain having the sequence according to any one of SEQ ID NOs. 7, 8, 9, 10, 11 or 12.

PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

-

Page/Page column 59, (2015/04/28)

Conjugates of specific PBD dimers with an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, or 10, optionally further comprising a VL domain having the sequence 5 according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 260418-25-5